Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lutetium-177 Labeled BQ7876 in Prostate Cancer
NCT06641219Phase 1Completed
- Sponsor
- Tomsk National Research Medical Centre of the Russian Academy of Sciences
- Start
- Oct 2024
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of [177Lu]Lu-BQ7876 in prostate cancer (PCa), sponsored by Tomsk National Research Medical Centre of the Russian Academy of Sciences. Primary endpoints: [177Lu]Lu-BQ7876 blood clearance at 48 hours, Gamma camera-based whole-body [177Lu]Lu-BQ7876 at 120 hours and 1 more. Started Oct 2024; status: completed.
02
Drugs
[177Lu]Lu-BQ7876
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT06641219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06641219.